Pretrial Clashes Intensify In Neurontin Off-Label MDL
With a trial in multidistrict litigation over Pfizer Inc.'s alleged off-label marketing of Neurontin barely more than a week away, the drugmaker is seeking depositions related to a Web site owned...To view the full article, register now.
Already a subscriber? Click here to view full article